AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31220570 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs considered clinically replicable
Number of subjects: 47
Study 31220570 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs with absent information
Number of subjects: 47
Study 31220570 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs with less well described information
Number of subjects: 47
Study 31220570 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs with best described information
Number of subjects: 47
Study 29070025 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DL-PDT) with methyl aminolevulinate (MAL), 5 treatments over 18 months, with daylight exposure for 2 hours after MAL application.
Number of subjects: 0
Study 29070025 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgery (control group), lesion-directed at the first visit and at visits 2 to 5 if necessary.
Number of subjects: 0
Study 29070025 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DL-PDT)
Number of subjects: 0
Study 29070025 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgery (control group)
Number of subjects: 0
Study 26312936 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclabendazole (TCBZ) 7.5mg/kg administered in two doses with a 12-hour interval (Group I)
Number of subjects: 84
Study 26312936 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclabendazole (TCBZ) 10mg/kg administered as a single dose (Group II)
Number of subjects: 84
Study 26312936 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group I and Group II)
Number of subjects: 84
Study 23937441 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) snack bar
Number of subjects: 14
Study 23937441 — intervention group
Group type: COMPARATOR
Intervention: High Glycemic Index (HGI) snack bar
Number of subjects: 14
Study 21632810 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ergocalciferol (50,000 IU)
Number of subjects: 12
Study 19629889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PUFA (100 mg fish oil/kg body weight/day)
Number of subjects: 102
Study 19629889 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 mg soya oil/kg body weight/day)
Number of subjects: 102
Study 19629889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PUFA
Number of subjects: 102
Study 19629889 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 16388789 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional road cyclists
Number of subjects: 85
Study 16388789 — intervention group
Group type: COMPARATOR
Intervention: Sedentary controls
Number of subjects: 85
Study 15599086 — intervention group
Group type: EXPERIMENTAL
Intervention: game‐with‐music
Number of subjects: 0
Study 15599086 — intervention group
Group type: EXPERIMENTAL
Intervention: music‐only
Number of subjects: 0
Study 15599086 — intervention group
Group type: COMPARATOR
Intervention: game‐without‐music
Number of subjects: 0
Study 11829208 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride at a dose of 100 mg/day
Number of subjects: 0
Study 11829208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9492495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 0
Study 9492495 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 7803945 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with bendroflumethiazide (2.5 mg/day, with possible doubling of dosage)
Number of subjects: 2100
Study 7803945 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with lisinopril (2.5 mg/day, with possible doubling of dosage)
Number of subjects: 2100
Study 7803945 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with slow release diltiazem (120 mg/day, increasing to 240 mg/day if required)
Number of subjects: 2100
Study 7803945 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 2100
Study 3190040 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclosporin A (10 mg/kg body weight.d)
Number of subjects: 31
Study 3190040 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin A (1 mg/kg.d)
Number of subjects: 31
Study 3190040 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotoxicity
Number of subjects: 31
Study 29778251 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based Tai chi (TC)
Number of subjects: 0
Study 29778251 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 28499440 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Brief Intervention (EBI) - five weekly sessions and one follow-up at 8 weeks
Number of subjects: 30
Study 28499440 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 30
Study 26203062 — intervention group
Group type: EXPERIMENTAL
Intervention: Erectile dysfunction
Number of subjects: 1244
Study 26203062 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (LUTS)
Number of subjects: 1244
Study 26203062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual dysfunction in women
Number of subjects: 1244
Study 26203062 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary incontinence (UI) and LUTS combined in women
Number of subjects: 1244
Study 26203062 — intervention group
Group type: EXPERIMENTAL
Intervention: Urologic complications
Number of subjects: 1244
Study 23601259 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (stylet replacement before needle removal)
Number of subjects: 630
Study 23601259 — intervention group
Group type: COMPARATOR
Intervention: Group B (needle removal without stylet replacement)
Number of subjects: 630
Study 21556731 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 nerve root stimulation
Number of subjects: 25
Study 18705518 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified type of retention elements (M group) with an adams clasp added in the position of central incisors.
Number of subjects: 18
Study 18705518 — intervention group
Group type: COMPARATOR
Intervention: Traditional type of retention elements (T group).
Number of subjects: 18
Study 16580422 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg three times a day for 4 weeks
Number of subjects: 48
Study 16580422 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 48
Study 16580422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12656697 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-stimulated gastric acid secretion in subjects with gastro-oesophageal reflux disease
Number of subjects: 85
Study 12656697 — intervention group
Group type: COMPARATOR
Intervention: Meal-stimulated gastric acid secretion in healthy controls
Number of subjects: 85
Study 12656697 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between meal-stimulated gastric secretion and integrated gastric acidity
Number of subjects: 85
Study 12656697 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between oesophageal acidity and integrated gastric acidity
Number of subjects: 85
Study 11134120 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation (exact dosage not specified)
Number of subjects: 780
Study 11134120 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake (1000 mg difference)
Number of subjects: 780
Study 11134120 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 780
Study 9172848 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors (higher state anxiety, lower anger outward, more past life events, lower expectations of future life events) in nonactive medication group (n = 263)
Number of subjects: 348
Study 9172848 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in past life events and depression from baseline to first follow-up
Number of subjects: 348
Study 8396989 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 65
Study 8396989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 2822797 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg
Number of subjects: 16
Study 2822797 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 16
Study 2822797 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 16
Study 2822797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31863680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 10
Study 31863680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 10
Study 31863680 — intervention group
Group type: EXPERIMENTAL
Intervention: TMAO
Number of subjects: 10
Study 31863680 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary fat intake in males
Number of subjects: 10
Study 29347887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo-assisted tumor resection en bloc with peritumoral tracer injection (blue dye)
Number of subjects: 17
Study 29347887 — intervention group
Group type: COMPARATOR
Intervention: Palliative tumor cryoablation in situ with intratumoral tracer injection (blue dye)
Number of subjects: 17
Study 28153938 — intervention group
Group type: COMPARATOR
Intervention: CTRL+DS (unrestricted breathing with 0.6-l dead space)
Number of subjects: 11
Study 28153938 — intervention group
Group type: COMPARATOR
Intervention: CTRL (unrestricted breathing at 90% gas exchange threshold)
Number of subjects: 11
Study 28153938 — intervention group
Group type: EXPERIMENTAL
Intervention: CWS+DS (chest wall strapping with 0.6-l dead space)
Number of subjects: 11
Study 28153938 — intervention group
Group type: COMPARATOR
Intervention: CWS (chest wall strapping at 90% GET)
Number of subjects: 11
Study 24419772 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on clinical signs/symptoms and complete blood count (CBC) data
Number of subjects: 125
Study 22248163 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplex T (tobramycin-laden) cement
Number of subjects: 23
Study 22248163 — intervention group
Group type: COMPARATOR
Intervention: Simplex P (standard) cement
Number of subjects: 23
Study 19403954 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull Energy Drink (ED; 2.0 g taurine, 1.2 g glucuronolactone, 160 mg caffeine, 54 g carbohydrate, 40 mg niacin, 10 mg pantothenic acid, 10 mg vitamin B6, and 10 microg vitamin B12)
Number of subjects: 12
Study 19403954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19403954 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull Energy Drink (ED)
Number of subjects: 12
Study 17985956 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sustained release morphine
Number of subjects: 38
Study 17985956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 15908668 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity (PA) intervention for early-stage breast cancer patients
Number of subjects: 86
Study 15908668 — intervention group
Group type: COMPARATOR
Intervention: Contact control group
Number of subjects: 86
Study 12043868 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite and Glyde File Prep (group C)
Number of subjects: 40
Study 12043868 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite and Glyde File Prep applied at the end of the preparation with sterile paper points (group D)
Number of subjects: 40
Study 12043868 — intervention group
Group type: COMPARATOR
Intervention: Physiological solution (group A)
Number of subjects: 40
Study 12043868 — intervention group
Group type: COMPARATOR
Intervention: 2.5% sodium hypochlorite (group B)
Number of subjects: 40
Study 11928421 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant retained overdentures (IRD)
Number of subjects: 151
Study 11928421 — intervention group
Group type: COMPARATOR
Intervention: Complete dentures (CD)
Number of subjects: 151
Study 7667819 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (200 mg thrice daily, with meals)
Number of subjects: 459
Study 7667819 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (300 mg thrice daily, with meals)
Number of subjects: 459
Study 7667819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 2140380 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 2140380 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0
Study 2140380 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 341967 — intervention group
Group type: EXPERIMENTAL
Intervention: Iris clip lens implantation after intracapsular cataract extraction
Number of subjects: 62
Study 341967 — intervention group
Group type: COMPARATOR
Intervention: Intracapsular extraction only
Number of subjects: 62
Study 30517087 — intervention group
Group type: EXPERIMENTAL
Intervention: RE40%1RM
Number of subjects: 12
Study 30517087 — intervention group
Group type: COMPARATOR
Intervention: CONT40%
Number of subjects: 12
Study 30517087 — intervention group
Group type: COMPARATOR
Intervention: CONT80%
Number of subjects: 12
Study 30517087 — intervention group
Group type: EXPERIMENTAL
Intervention: RE80%1RM
Number of subjects: 12
Study 28202786 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (dopaminergic antagonist)
Number of subjects: 0
Study 28202786 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (dopaminergic agonist)
Number of subjects: 0
Study 28202786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25799193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground fish (952 mg of elemental calcium)
Number of subjects: 96
Study 25799193 — intervention group
Group type: COMPARATOR
Intervention: Limestone (920 mg of elemental calcium)
Number of subjects: 96
Study 23374907 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training (early intervention group, EI)
Number of subjects: 30
Study 23374907 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training (late intervention group, LI)
Number of subjects: 30
Study 23374907 — intervention group
Group type: COMPARATOR
Intervention: Comparison intervention (early intervention group, EI)
Number of subjects: 30
Study 23374907 — intervention group
Group type: COMPARATOR
Intervention: Comparison intervention (late intervention group, LI)
Number of subjects: 30
Study 21546602 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-supported training
Number of subjects: 45
Study 21546602 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 45
Study 19577352 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent peritonitis episodes
Number of subjects: 125
Study 19577352 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapsing peritonitis episodes
Number of subjects: 125
Study 19577352 — intervention group
Group type: COMPARATOR
Intervention: Control group (first peritonitis episodes)
Number of subjects: 125
Study 16728218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES) implantation followed by treatment for restenosis with bare metal stent implantation, balloon dilatation, or intravascular brachytherapy; 82% received bare metal stent implantation, 13.5% balloon dilatation, and 4.5% intravascular brachytherapy.
Number of subjects: 22
Study 16728218 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional percutaneous coronary intervention for SES failure.
Number of subjects: 22
Study 16176337 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive medicines
Number of subjects: 28997
Study 12939217 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of hypoxic gas mixture corresponding to an altitude of 4500 m (controls)
Number of subjects: 18
Study 12939217 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of hypoxic gas mixture corresponding to an altitude of 2500 m (CAD patients)
Number of subjects: 18
Study 10425945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel‐titanium hand files
Number of subjects: 60
Study 10425945 — intervention group
Group type: COMPARATOR
Intervention: Stainless‐steel K‐files
Number of subjects: 60
Study 7572678 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily
Number of subjects: 9014
Study 7572678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study 2075121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg p.o.)
Number of subjects: 14
Study 2075121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6973988 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluproquazone 200 mg
Number of subjects: 138
Study 6973988 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg
Number of subjects: 138
Study 6973988 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluproquazone 100 mg
Number of subjects: 138
Study 6973988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 31166961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine/Ginkgo biloba extract combination drug (Yuclid)
Number of subjects: 4831
Study 28368352 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin (3 mg, group M) twice daily
Number of subjects: 64
Study 28368352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 64
Study 28368352 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin (3 mg, group M)
Number of subjects: 64
Study 26186658 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin in crushed tablet form (n=10)
Number of subjects: 20
Study 26186658 — intervention group
Group type: COMPARATOR
Intervention: Roxithromycin in conventional tablet form (n=10)
Number of subjects: 20
Study 24222666 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite PAD (ABI <0.90)
Number of subjects: 1566
Study 24222666 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline PAD (ABI 0.90 to 0.99)
Number of subjects: 1566
Study 24222666 — intervention group
Group type: EXPERIMENTAL
Intervention: Low normal ABI (ABI 1.00 to 1.09)
Number of subjects: 1566
Study 24222666 — intervention group
Group type: EXPERIMENTAL
Intervention: No PAD (ABI 1.10 to 1.40)
Number of subjects: 1566
Study 24222666 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic participants with PAD
Number of subjects: 1566
Study 21951682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide (VMPT-VT)
Number of subjects: 140
Study 21951682 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib-melphalan-prednisone (VMP)
Number of subjects: 140
Study 18504393 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.058 IU.kg(‐1).day(‐1))
Number of subjects: 48
Study 17140161 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (iso-osmolar contrast media)
Number of subjects: 221
Study 17140161 — intervention group
Group type: COMPARATOR
Intervention: Iopromid (low-osmolar contrast media)
Number of subjects: 221
Study 14502378 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber band ligation
Number of subjects: 100
Study 14502378 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared coagulation
Number of subjects: 100
Study 10732318 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 10
Study 10732318 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 5 mg
Number of subjects: 10
Study 10732318 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg
Number of subjects: 10
Study 10732318 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg, Metoclopramide 5 mg, Domperidone 10 mg
Number of subjects: 10
Study 8615482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution (6 and 12 mL/kg isovolemic exchange of blood for 6% hydroxyethyl starch)
Number of subjects: 90
Study 8615482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution
Number of subjects: 90
Study 8615482 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 1486544 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate control achieved by verapamil
Number of subjects: 18
Study 1486544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioversion to normal sinus rhythm
Number of subjects: 18
Study 1486544 — intervention group
Group type: EXPERIMENTAL
Intervention: Post cardioversion
Number of subjects: 18
Study 1486544 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after cardioversion
Number of subjects: 18
Study 1486544 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial size measurement
Number of subjects: 18
Study 6539363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 6539363 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0
Study 29671255 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Diquafosol Tetrasodium (3% DQS)
Number of subjects: 27
Study 29671255 — intervention group
Group type: COMPARATOR
Intervention: Artificial Tear (preservative-free AT)
Number of subjects: 27
Study 26777769 — intervention group
Group type: EXPERIMENTAL
Intervention: DGG + Ozone Therapy (OT)
Number of subjects: 30
Study 26777769 — intervention group
Group type: COMPARATOR
Intervention: DGG alone (Control)
Number of subjects: 30
Study 24525659 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2624 40 mg
Number of subjects: 0
Study 24525659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24525659 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg
Number of subjects: 0
Study 23190222 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir-ritonavir-based ART
Number of subjects: 176
Study 23190222 — intervention group
Group type: COMPARATOR
Intervention: NNRTI-based ART
Number of subjects: 176
Study 20187284 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein-leucine drink after resistance exercise (B)
Number of subjects: 6
Study 20187284 — intervention group
Group type: COMPARATOR
Intervention: Fasted state (F)
Number of subjects: 6
Study 18165639 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-based combinations with anthracycline
Number of subjects: 22903
Study 15624096 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (3 weeks treatment)
Number of subjects: 10